论文部分内容阅读
目的：探讨支气管动脉灌注（ＢＡＩ）治疗中晚期肺癌的临床疗效。方法：对９７例平均年龄５６岁Ⅱ期－Ⅳ期肺癌患者实行１次或多次ＢＡＩ治疗，根据病理类型选择不同的抗癌药物，以肺癌细胞对药物敏感度适当调整药物种类及剂量，并分析临床效果。结果：完全缓解（ＣＲ）１９例（１９．５９％），部分缓解（ＰＲ）５９例（６０．８２％），无变化（ＮＣ）１５例（１５．４６％），进展（ＰＤ）４例（４．１２％），有效率（ＣＲ＋ＰＲ）８０．４１％，三年生存率４６１２％。结论：支气管动脉灌注（ＢＡＩ）治疗中晚期肺癌疗效确切，近期疗效好，小细胞未分化癌效果显著，鳞癌次之，腺癌最差，病期越早，疗效越好，富血管型肿瘤的疗效显著高于少血管型。治疗中应防止严重并发症的发生。
Objective: To investigate the clinical efficacy of bronchial arterial infusion (BAI) in the treatment of advanced lung cancer. Methods: 97 cases of stage II-IV lung cancer patients with an average age of 56 years were treated with BAI therapy one or more times. Different types of anticancer drugs were selected according to the pathological type. The type and dosage of lung cancer cells were appropriately adjusted for drug sensitivity. Analyze the clinical effect. Results: Complete remission (CR) was 19 cases (19.59%), partial remission (PR) was 59 cases (60.82%), no change (NC) 15 cases (15.46%), progress (PD) 4 cases (4.12%), the effective rate (CR+PR) was 80.41%, and the three-year survival rate was 4612%. Conclusion: BAI has a definite curative effect in the treatment of advanced lung cancer. The short-term efficacy is good. The effect of small cell undifferentiated carcinoma is significant. The squamous cell carcinoma is the next, and the adenocarcinoma is the worst. The earlier the disease is, the better the effect is. The efficacy is significantly higher than that of the small vessel type. Treatment should prevent serious complications.